SEC Seal
SEC Banner
Search the Next-Generation EDGAR System
Filing Detail
Form 4 - Statement of changes in beneficial ownership of securities:
SEC Accession No. 0001104659-24-034093
Filing Date
2024-03-13
Accepted
2024-03-13 20:56:54
Documents
1
Period of Report
2024-03-11

Document Format Files

Seq Description Document Type Size
1 OWNERSHIP DOCUMENT tm248822-3_4seq1.html 4  
1 OWNERSHIP DOCUMENT tm248822-3_4seq1.xml 4 3695
  Complete submission text file 0001104659-24-034093.txt   5545
Mailing Address 1325 AVENUE OF AMERICAS 28TH FLOOR NEW YORK NY 10019
Business Address 1325 AVENUE OF AMERICAS 28TH FLOOR NEW YORK NY 10019 201-488-0460
BRAINSTORM CELL THERAPEUTICS INC. (Issuer) CIK: 0001137883 (see all company filings)

IRS No.: 207273918 | State of Incorp.: DE | Fiscal Year End: 1231
SIC: 2836 Biological Products, (No Diagnostic Substances)
(CF Office: 03 Life Sciences)

Mailing Address C/O BRAINSTORM CELL THERAPEUTICS, INC. 605 THIRD AVENUE, 34TH FLOOR NEW YORK NY 10158
Business Address
Yablonka Uri (Reporting) CIK: 0001608814 (see all company filings)

Type: 4 | Act: 34 | File No.: 001-36641 | Film No.: 24747667